MOUNTAIN VIEW, Calif., Sept. 7 /PRNewswire/ — MAP
Pharmaceuticals, Inc. (Nasdaq:
MAPP) today announced that the Company will participate in the
following healthcare conferences in September:
Morgan Stanley Global Healthcare Conference
Tuesday, September 14, at 11:30 a.m. ET in New York
Stifel Nicolaus 2010 Healthcare ConferenceWednesday, September
15, at 2:05 p.m. ET in Boston
UBS Global Life Sciences Conference
Tuesday, September 21, at 9:00 a.m. ET in New York
A live webcast of the events will be available on the Investor
Relations section of MAP Pharmaceuticals’ website at http://www.mappharma.com. A
replay will also be available within 24 hours following the
presentation.
In addition, the Company will be presenting its LEVADEX™
orally inhaled migraine therapy Phase 3 data at the American
Neurological Association’s 135th Annual Meeting on Monday,
September 13, at 1:00 p.m. in San Francisco.
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and
commercializing new therapies for patients suffering from
conditions that are not adequately treated by currently available
medicines. The company is developing LEVADEX orally inhaled therapy
for the potential treatment of migraine and has reported positive
results from the efficacy portion of its Phase 3 trial of LEVADEX.
In addition, MAP Pharmaceuticals generates new pipeline
opportunities by applying its proprietary drug particle and
inhalation technologies to enhance the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
CONTACTS:Nicole Foderaro WCG(415) 946-1058
